

DMDG past Open and Joint meeting programmes

Joint Meeting 2014

- in partnership with the GMP (Groupe de Métabolisme et Pharmacocinétique)

22-24 October 2014 - Paris, France

Wednesday 22 October 2014

- 11.00-13.00 **Arrival, registration & lunch**
- 13.00-13.25 **Chairs' Opening address**
Kevin Brady, Roche & Nathalie Wagner, Galderma
- 13.30-14.45 **Keynote Speaker: Translational Drug Metabolism and Pharmacokinetics : Past, Present and Future**
Prof Jean-Michel Scherrmann, Faculty of Pharmacy, University of Paris Descartes
- 14.45-15.15 Tea break
- 15.15-17.00 **Modelling *in vitro* DMPK data**
Chairs: Krishna Machavaram, Simcyp & Marion Diaz, Ipsen
Speakers:
Identifying mathematical models of *in vitro* kinetics
James W. T. Yates, Astra Zeneca, Macclesfield, UK
***In vitro* to *in vivo* extrapolation of active drug transport in the gut wall – Roles of proteomics and modeling of *in vitro* data**
Aki T. Heikkinen, Admescope Ltd, Oulu, Finland
The application of PBPK modelling to investigate the OCT/MATE transporter DDI between metformin and cimetidine
Howard J. Burt, Simcyp Ltd (a Certara company), Sheffield, UK
- 17.05-17.45 **Student Presentations (Poster Blitz)**
Chairs: Laura Hinton, Cyprotex & Nathalie Wagner, Galderma
- 17.45-19.00 **Posters**
Chairs: Laura Hinton, Cyprotex & Nathalie Wagner, Galderma
- 19.00 **DINNER - Free Choice**

Thursday 23 October 2014

- 08.30-10.00 **Free Communications**
Chair: Becky Scott, GSK
Combining Accelerator Mass Spectrometry and Imaging Mass Spectrometry for the Validation of Quantitative Tissue Imaging Methods
Bianca Squillaci, GSK
Blood concentrations of hydroxychloroquine and its metabolites in hydroxychloroquine-poisoned patients. usefulness on admission to the intensive care unit and pharmacokinetics
Emmanuel Bourgogne, AP-HP, Hôpital Lariboisière, Paris, France
ICP-MS as an excellent detector in DMPK / ADME
Jaap Wieling QPS, Groningen
- 10.00-10.30 **Coffee break**
- 10.30-12.00 Disposition of proteins, RNA and other large molecules
Chairs: Simone Schadt, Roche & Olivier Petricoul, Novartis
Speakers:
Identification of an active catabolic metabolite of the fusion protein Tetranectin-Apolipoprotein A1 in rabbit
Simone Schadt, Roche
Exploring the Metabolism of Peptides in Drug Discovery
Jørgen Olsen Novo Nordisk
Assessment of Antisense Oligonucleotide Disposition in cells
Erich Koller Roche

- 12.00-14.00 Lunch (13.15-14.00 GMP General Assembly)
- 14.00-15.30 **Disposition of proteins, RNA and other large molecules**
Chairs: Simone Schadt, Roche & Olivier Petricoul, Novartis
 Speakers:
What information on disposition is needed for the safety assessment of biologics?
Jennifer Sims, Integrated Biologix
Typical and atypical disposition of antibodies - implications for safety
Peter Theil, UCB
Safety of biologics: Clinical Pharmacology and DMPK strategy for IND and BLA submissions
Balaji Agoram, MedImmune
- 15.30-16.00 **Tea break**
- 16.00-18.00 **DMPK aspects impacting clinical trial design**
Chairs: Rob Stubbs, GSK & Laurent Nguyen, Pierre-Fabre
 Speakers:
Recent developments of the maturation functions used for PK predictions in paediatrics
Prof Michel Tod ISPB, University of Lyon, France
Differences and similarities between paediatric and adult patients: Relevance for PKPD modelling
Prof Gerard Pons, University Paris Descartes – Cochin, St Vincent de Paul, France
Strengths and weaknesses around paediatric pharmacology modelling and simulations and/or novel pediatric transporter expression data
Saskia de Wildt, Erasmus MC Sophia Children's Hospital, The Netherlands
- 19.30 **Conference Dinner & Entertainment (Bateaux Mouches River Cruise)**
- Friday 24 October 2014**
- 09.15-10.30 **Parallel Sessions - Session A. Bioanalysis and Beyond**
Chairs: Kirsty Jackson-Addie, AstraZeneca & Becky Scott, GSK
 Speakers:
Bioanalysis and Beyond
Prof Tony Edge, University of Liverpool/Thermo Scientific
Ion Mobility-Mass Spectrometry in Protein Structure; Development of Cost-Effective Platforms for IM-MS characterization
Rebecca Beveridge, Manchester Institute of Biotechnology, University of Manchester
Non-Invasive approaches to metabolomics; breath, skin and saliva
James Reynolds, Centre for Analytical Science, Loughborough University
- Parallel Sessions - Session B. Is DMPK the missing link in personalised medicine?**
Chairs: Antonin Schmitt, University of Burgundy & Joseph Ciccolini, University of Aix/Marseille
 Speakers:
Integrating pharmacogenetic testing at the bedside: yes we can!
Dr. Joseph Ciccolini University of Aix/Marseille
Dose Individualisation of anticancer drugs: pharmacogenetic criteria versus other characteristics
Prof Etienne Chatelut, Faculty of Pharmacy, Université Paul Sabatier, Toulouse
SNiPer. Mission: tailoring Tacrolimus therapy in renal transplantation. Target: ABC and CYPs genes. Is it impossible?
Prof Laure Elens, Louvain University, Belgium
- 10.15-10.30 **Coffee break**
- 10.30-12.30 **Back to the Bench-the backward translation of clinical data**
Chairs: Suzanne Iverson, AstraZeneca & Vassili Aslanis, Novartis
 Speakers:
Challenges in CYP-reaction phenotyping or when clinical data do not match *in vitro* data – Case study with Brivaracetam
Hugues Chanteux UCB Pharma, Belgium
Translational reasoning for compounds affecting energy intake and body weight
Peter Gennemark AstraZeneca, Mölndal, Sweden
- 12.30-12.45 **Closing Remarks**
- 12.45-14.00 **Lunch and depart**